Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer

European Journal of Cancer

Volumn 50, Issue 7, 2014, Pages 1269-1275

  Jehn, C F ^a   Boning L ^b   Kroning H ^c   Pezzutto, A ^a   Luftner D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Onkologische Praxis Elisenhof   (Germany)

^c Schwerpunktpraxis für Haematologie und Onkologie Hasselbachplatz   (Germany)

Author keywords

Cetuximab; Comorbidity; Elderly patients; Irinotecan pretreated; Metastatic colorectal cancer

Indexed keywords

CETUXIMAB; IRINOTECAN;

ADULT; AGED; ALLERGY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GERIATRIC CARE; GROUPS BY AGE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

CETUXIMAB; COMORBIDITY; ELDERLY PATIENTS; IRINOTECAN-PRETREATED; METASTATIC COLORECTAL CANCER;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED;

EID: 84897406141     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.01.005     Document Type: Article

References (25)

1. National Cancer Institute, Surveillance, epidemiology and end results. http://seer.cancer.gov/statfacts/ (3 June 2010).
2. L.C. Walter, and K.E. Covinsky Cancer screening in elderly patients: a framework for individulized decision making JAMA 285 21 2001 Jun 6 2750 2756
3. R.M. Goldberg, I. Tabah-Fisch, and H. Bleiberg et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer J Ciln Oncol 24 2006 4085 4091
4. F. Kabbinavar, H. Hurwitz, and J. Yi et al. Addition of bevacizumab of fluorouracil-based first line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials J Clin Oncol 27 2009 199 205
5. H. Sanoff, H. Bleiberg, and R. Goldberg Managing older patients with colorectal cancer J Clin Oncol 25 2007 1891 1897
6. V.E.P.P. Lemmens, A.H. van Halteren, and M.L.G. Janssen-Heijnen et al. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity Ann Oncol 16 2005 767 772
7. J.H. Lewis, M.L. Kilgore, and D.P. Goldman et al. Participation of patients 65 years of age or older in cancer trials J Clin Oncol 21 2003 1383 1389
8. M. Extermann Measuring comorbidity in older cancer patients Eur J Cancer 36 2000 453 471
9. M.E. Charlson, P. Pompei, and K.L. Ales et al. A new method of classifying prognostic comorbidity in longitudinal studies; development and validation J Chronic Dis 40 1987 373 383
10. W.H. Hall, R. Ramachandran, and S. Narayan et al. An electronic application for rapidly calculating Charlson comorbidity score BMC Cancer 4 2004 94
11. R. Rieker, E. Hammer, and R. Eisele et al. The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection Langenbecks Arch Surg 387 2002 72 76
12. A. Imai KTakaoka Comparing antibody and small-molecule therapies for cancer Nat Rev Cancer 6 2006 714 727
13. S. Li, K.R. Schmitz, and P.D. Jeffrey et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311
14. T.J. Price, D. Zannino, and K. Wilson et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C Ann Oncol 23 6 2012 Jun 1531 1536
15. H. Wilke, R. Glynne-Jones, and J. Thaler et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study J Clin Oncol 26 2008 5335 5343
16. D. Cunningham, Y. Humblet, and S. Siena et al. Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345
17. L.B. Saltz, H.J. Lenz, and L. Hedy et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 2007 4557 4561
18. B. Vincenzi, D. Santini, and C. Rabitti et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial BJC 94 2006 792 797
19. G. Folprecht, D. Cunningham, and P. Ross et al. Efficacy of 5-FU-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann Oncol 15 2004 1330 1338
20. R. Perez-Soler, A. Chahoua, and L.A. Hammond et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer J Clin Oncol 22 2004 3238 3247
21. C. Giessen, R.P. Laubender, and D.P. Ankerst et al. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials Clin Cancer Res 19 1 2013 225 235 10.1158/1078-0432.CCR-12-1515 [Epub 2012 Nov 13]
22. M.M. Vickers, E.D. Powell, and T.R. Asmis et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo Eur J Cancer 48 10 2012 1434 1442 10.1016/j.ejca.2011.10.035 [Epub 2011 Nov 24]
23. L. Saltz, M. Rubin, and H. Hochster et al. Cetuximab plus irinotecan is active in irinotecan-refractory colorectal cancer that expresses epidermal growth factor (EGFR) Proc Am Soc Clin Oncol 20 2001 3a
24. R. Lim, Y. Sun, and S.A. Im et al. Cetuximab plus irinotecan in pretreated metastastic colorectal cancer patients: The ELISE study World J Gastroenterol 17 14 2011 April 14 1879 1888
25. L. Saltz, M. Kies, and J.L. Abbruzzese et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies Proc Am Soc Clin Oncol 22 2003 204